Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
After reaching FDA first, CRISPR-Vertex's gene editing therapy will get 'benign' review by committee
A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ ...
Europe’s health regulator followed the United States and the United Kingdom in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...
A U.S. flag flies next to the headquarters of Vertex in Boston (Reuters) -Vertex Pharmaceuticals sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a ...
A NEW RAY OF HOPE FOR THOUSANDS OF PEOPLE WITH SICKLE CELL DISEASE. TODAY, THE FDA APPROVING TWO GENE BASED TREATMENTS. HERE TO TALK ABOUT IT IS DR. TODD ELLERIN, DEPUTY CHAIR OF MEDICINE AT SOUTH ...
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP) for those aged 12 ...
Vertex's comprehensive approach has already shaped the treatment of CF and earned it a dominant position worldwide. The chronic nature of therapy and limited competition on the horizon heighten the CF ...
A group of independent experts to the US FDA for the most part embraced a first of its kind gene editing therapy developed by CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharma (NASDAQ:VRTX) for ...
Casgevy, the first drug approved in the United States to use the revolutionary gene-editing tool called CRISPR-Cas9, was cleared by regulators on Tuesday to treat a second rare blood disorder. About ...
After a long development road, the first CRISPR-based gene editing therapy recently cleared a FDA advisory committee and appears to be nearing its U.S. launch. Vertex Pharmaceuticals, awaiting the ...
Europe’s health regulator followed the US and UK in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG treatment for sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results